title: Anaphylaxis: implications of monoclonal antibody use in oncology.
abstract: Anaphylaxis is currently classified as an immunologically triggered response with reactions that are IgE-mediated and reactions that are not IgE-mediated. This immunologically mediated phenomenon can result in various clinical manifestations, including decreased blood pressure, generalized skin inflammation, such as hives and pruritus, and respiratory symptoms, such as wheezing or bronchospasm. The severity of anaphylaxis can range from a mild allergic reaction to a potentially fatal anaphylactic shock. Numerous causative agents trigger anaphylactic reactions, and some of the best described include food and bee sting allergens. Monoclonal antibodies, which are increasingly used in the treatment of various malignancies, also can cause anaphylaxis. In this review, the mechanisms governing anaphylaxis along with treatment strategies are reviewed. Diagnostic aids for anaphylaxis are also discussed. Increased awareness of the mechanisms, symptoms, and treatment of anaphylaxis can aid caregivers to make informed decisions when new agents, such as monoclonal antibodies, are introduced into the clinic.
authors.affiliation: Department of Dermatology, University of Utah, Health Sciences Center, Salt Lake City, Utah, USA. gerald.gleich@hsc.utah.edu
authors.forename: Gerald J
authors.initials: GJ
authors.lastname: Gleich
authors.forename: Kristin M
authors.initials: KM
authors.lastname: Leiferman
mesh_terms: D000707:Anaphylaxis / Q000139:chemically induced*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000209:etiology; D006801:Humans; D008495:Medical Oncology; D009369:Neoplasms / Q000628:therapy
chemical_list: D000911:Antibodies, Monoclonal